Answers are grounded in this paper and cite their sources.
Four previously unreported glycosylated linear polyene polyketides, kofumicins A−D (1−4), were isolated from Kutzneria kofuensisNRRL 24061 and were found to inhibit Staphylococcus aureus growth. The kofumicins were identified from the crude extract using a bacterial activity metabolomics-guided approach, which employs split-flow HPLC-UV/MS to generate microtiter plate arrays enabling dereplication and bioactivity assessment prior to isolation. The structures were determined using NMR data, HR-ESI-MS, and biosynthetic gene cluster inference, establishing the kofumicins as new members of a family of glycosylated amphoteric linear polyene polyketides. Kofumicins A−C (1−3) share a conserved polyketide chain but differ in disaccharide composition and glycosidic regiochemistry, while kofumicin D (4) exhibits a truncated polyketide chain with a monosaccharide. Distance-constrained molecular dynamics calculations suggest that the kofumicins adopt a bent bolaamphiphilic conformation. Kofumicin C (3), bearing 6-deoxyglucose as the polyketide-linked sugar, was the most potent glycovariant tested, with MICs of 2−4 μg/mL against S. aureus strains including MRSA, while kofumicin B (2), bearing a glucose at the same position, exhibited MICs of 16−32 μg/mL. These results identify the C-6 substituent of the polyketide-linked sugar as an important determinant of antibacterial potency in this compound class.
No takes yet. Share an insight, caveat, or question.
Schares et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: